Cat. No.: HY-N3298

Meranzin

Customer Review

Based on 1 Customer Validation

Meranzin is an orally active antidepressant and GHSR modulator. Meranzin significantly upregulates the expression levels of brain-derived neurotrophic factor and p-mTOR in the hippocampus via the ghrelin-growth hormone secretagogue receptor pathway. Meranzin regulates blood oxygen level-dependent signals in the hippocampus-thalamus-basal ganglia circuit, attenuates reward system activation, and promotes the normalization of related hormone levels. Meranzin effectively ameliorates depression-like behaviors and gastrointestinal hypomotility, and can be used in research related to depression and major depressive disorder.

For research use only. We do not sell to patients.

Purity: 98.0%
CAS No.: 23971-42-8
Formula: C₁₅H₁₆O₄
Molecular Weight:260.29

Storage:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Meranzin Chemical Structure

CAS No.: 23971-42-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All mTOR Isoforms :

All GHSR Isoforms :

GHSR1a

In Vivo

Meranzin (9-18 mg/kg; single dose) improves depression-like behaviors and hypomotility in acute forced swimming-induced rats via ghrelin-related regulation of hippocampal BDNF/p-mTOR signaling and HTB circuit activity^[1].
Meranzin (18 mg/kg; single dose) reduces depression-like behavior in wild-type mice as measured by FST and TST outcomes^[1].
Meranzin (18 mg/kg; single dose) does not reduce depression-like behavior in GHSR KO mice as measured by FST and TST outcomes^[1].
Meranzin (10 mg/kg; i.g.; daily; 7 days) produces significant antidepressant- and anxiolytic-like effects in UCMS-induced depressed rats, normalizes HPA axis function, increases hippocampal BDNF expression, and repairs UCMS-induced aberrant BOLD activation in the reward and limbic systems^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague-Dawley (8 rats per group; acute forced swimming-induced model)^[1]
Dosage:

9 mg/kg; 18 mg/kg
Administration:

single dose
Result:

Improved depression-like behavior (FST, OFT) and hypomotility (GE, IT) (all P<0.05).
Significantly stimulated BDNF and p-mTOR protein expressions in the hippocampus (both P<0.01).
Modulated activity in the hippocampus-thalamus-basal ganglia (HTB) circuits as measured by BOLD foci.
Had its effect on FST and GE inhibited by ghrelin antagonist [D-Lys3]-GHRP-6 (P<0.05).
Had its stimulation of hippocampal BDNF and p-mTOR expressions prevented by [D-Lys3]-GHRP-6 (P<0.01).
Had its modulation of HTB circuit activity inhibited by [D-Lys3]-GHRP-6.

Animal Model:

Wild-type (8 mice per group)^[1]
Dosage:

18 mg/kg
Administration:

single dose
Result:

Alleviated depression-like behavior (FST, TST) in wild-type mice.

Animal Model:

Growth hormone secretagogue receptor knockout (GHSR KO)^[1]
Dosage:

18 mg/kg
Administration:

single dose
Result:

Showed no antidepressant effects in GHSR KO mice, with no observed changes in FST or TST outcomes.

Animal Model:

Wistar (adult male, 180−220 g, UCMS-induced depression model)^[2]
Dosage:

10 mg/kg
Administration:

i.g.; daily; 7 days
Result:

Significantly reduced immobility time in the forced swimming test (P < 0.001 vs UCMS group).
Significantly increased sucrose preference index (P < 0.01 vs UCMS group).
Significantly increased total distance travelled in the open-field test (P < 0.01 vs UCMS group).
Significantly reduced plasma adrenocorticotropic hormone (ACTH) (P < 0.05 vs UCMS group), corticosterone (CORT) (P < 0.01 vs UCMS group), and acylated ghrelin (AG) (P < 0.01 vs UCMS group) levels, normalizing them to near control levels.
Significantly increased brain-derived neurotrophic factor (BDNF) expression in the hippocampal dentate gyrus (P < 0.01 vs UCMS group).
Attenuated UCMS-induced increased BOLD activation in reward system and limbic system brain regions, including the striatum, septal area, thalamus lateral nucleus group, bed nucleus of stria terminalis, hippocampus, midbrain superior colliculus, nucleus accumbens, and third ventricle.
Increased BOLD activation in the right auditory cortex, right amygdaloid body, left sensory cortex, right third ventricle, and left temporal association cortex.
Reversed UCMS-induced changes in BOLD signals in the right amygdaloid body and right visual cortex, and decreased BOLD signals in bilateral hypothalamus preoptic regions.

Chemical Information

CAS No. 23971-42-8
Appearance Solid
Molecular Weight 260.29
Formula C₁₅H₁₆O₄
Color White to off-white
SMILES

COC1=CC=C(C=C2)C(OC2=O)=C1C[C@H](O3)C3(C)C
Structure Classification
- Phenylpropanoids
- Coumarins
Initial Source
- Plants
- other families
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (384.19 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.8419 mL

19.2093 mL

38.4187 mL

5 mM

0.7684 mL

3.8419 mL

7.6837 mL

10 mM

0.3842 mL

1.9209 mL

3.8419 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Liu YL, et al. Meranzin Hydrate Improves Depression-Like Behaviors and Hypomotility via Ghrelin and Neurocircuitry. Chinese journal of integrative medicine. 2023 Jun;29(6):490-499. [Content Brief]

[2]. Liu X, et al. Meranzin hydrate elicits antidepressant effects and restores reward circuitry. Behavioural brain research. 2021 Feb 01;398:112898. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.8419 mL	19.2093 mL	38.4187 mL	96.0467 mL
	5 mM	0.7684 mL	3.8419 mL	7.6837 mL	19.2093 mL
	10 mM	0.3842 mL	1.9209 mL	3.8419 mL	9.6047 mL
	15 mM	0.2561 mL	1.2806 mL	2.5612 mL	6.4031 mL
	20 mM	0.1921 mL	0.9605 mL	1.9209 mL	4.8023 mL
	25 mM	0.1537 mL	0.7684 mL	1.5367 mL	3.8419 mL
	30 mM	0.1281 mL	0.6403 mL	1.2806 mL	3.2016 mL
	40 mM	0.0960 mL	0.4802 mL	0.9605 mL	2.4012 mL
	50 mM	0.0768 mL	0.3842 mL	0.7684 mL	1.9209 mL
	60 mM	0.0640 mL	0.3202 mL	0.6403 mL	1.6008 mL
	80 mM	0.0480 mL	0.2401 mL	0.4802 mL	1.2006 mL
	100 mM	0.0384 mL	0.1921 mL	0.3842 mL	0.9605 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Meranzin

GPCR/G Protein Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Autophagy Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cysteine Targeted Covalent Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

All mTOR Isoforms

All GHSR Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Meranzin Related Classifications

HY-N3298 Related Classifications